BeStock  
Stocks › Biotechnology › REGN

Regeneron Pharmaceuticals REGN

US equityMarket cap rank #226BiotechnologyInfectious Disease
$904.35 +$1.45 (+0.16%)
Market closed · Nov 7, 9:50 pm ET · Last extended-hours $900.00 -0.48%
Open$887.22
Prev close$902.90
Day range$887.04 – $911.64
Volume1.12M
Market cap$93.55B
P/E (TTM)20.0
Dividend yield0.41%

Earnings

Average move on report day±5.2%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+13.3%
Worst reaction-9.2%

Stock move on the day after each report

-1.3%2023/Q4+3.8%2024/Q1+1.3%2024/Q2-9.2%2024/Q3+4.5%2024/Q4-6.9%2025/Q1+2.5%2025/Q2+11.8%2025/Q3-1.1%2025/Q4-6.2%2026/Q1+6.2%2026/Q2+13.3%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q330 Oct 2026Pre Market±5.7%+13.33%Bigger than priced
2026/Q230 Jul 2026Pre Market±5.7%+6.17%Bigger than priced
2026/Q129 Apr 2026Pre Market±6.8%-6.21%Within range
2025/Q430 Jan 2026Pre Market±6.2%-1.07%Within range
2025/Q328 Oct 2025Pre Market±5.3%+11.82%Bigger than priced
2025/Q21 Aug 2025Pre Market±8.4%+2.46%Within range
2025/Q129 Apr 2025Pre Market±5.9%-6.87%Bigger than priced
2024/Q44 Feb 2025Pre Market±5.6%+4.53%Within range
2024/Q331 Oct 2024Pre Market±3.9%-9.17%Bigger than priced
2024/Q21 Aug 2024Pre Market±5.0%+1.29%Within range
2024/Q12 May 2024Pre Market±4.2%+3.78%Within range
2023/Q42 Feb 2024Pre Market±3.8%-1.32%Within range
2023/Q32 Nov 2023Pre Market±5.0%+3.48%Within range
2023/Q23 Aug 2023Pre Market±4.3%+5.37%Bigger than priced
2023/Q14 May 2023Pre Market±4.1%-6.14%Bigger than priced
2022/Q33 Nov 2022Pre Market±4.2%-0.24%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q2

By business line

  • Collaboration revenue$2.46B 57.2%
  • EYLEA HD$596.30M 13.9%
  • EYLEA$412.20M 9.6%
  • Libtayo$342.60M 8.0%
  • Other revenue$193.30M 4.5%
  • Libtayo$146.80M 3.4%
  • Praluent$74.70M 1.7%
  • Evkeeza$53.30M 1.2%
  • Lynozyfic$16.50M 0.4%

Fundamentals

Full statements →

Latest reported quarter: Q3, ended Sep 2026

Revenue$5.12B+36.3% YoY
Operating profit$2.07B+86.5% YoY
Net profit$1.95B+33.5% YoY
Diluted EPS$18.45+35.5% YoY
Free cash flow$1.43B+3.9% YoY
Operating cash flow$1.78B

Revenue, last 8 quarters

$3.8BDec '24$3.0BMar '25$3.7BJun '25$3.8BSep '25$3.9BDec '25$3.6BMar '26$4.3BJun '26$5.1BSep '26

Net profit, last 8 quarters

$917.7MDec '24$808.7MMar '25$1.4BJun '25$1.5BSep '25$844.6MDec '25$727.2MMar '26$1.3BJun '26$1.9BSep '26

Profitability & balance sheet

Gross margin85.8%
Operating margin30.4%
Net margin28.5%
Return on equity14.9%
Return on assets11.4%
Return on invested capital12.0%
Current ratio3.35
Liabilities / assets24.6%
Cash & investments$9.30B
Total debt$1.99B
Net cash (debt)$7.31B
Free cash flow / sales21.5%

Discussion

No comments yet — be the first to weigh in on REGN.

Sign in to join the discussion.

Scroll to Top